ASH

Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout
Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout
Biopharma Dive
ASH
Celgene
M&A
Bristol-Myers Squibb
liso-cel
Flag link:
Waiting for bluebird bio to Sing at ASH
Waiting for bluebird bio to Sing at ASH
Motley Fool
Bluebird Bio
earnings
ASH
CAR-T
Flag link:
#ASH17: Late breaker from AbbVie, Roche highlights a blockbuster breakout opportunity for Venclexta in CLL
#ASH17: Late breaker from AbbVie, Roche highlights a blockbuster breakout opportunity for Venclexta in CLL
Endpoints
ASH
AbbVie
Roche
Venclexta
CLL
chronic lymphocytic leukemia
Flag link:
9 Notable Biotechs Presenting At This Year's ASH Meeting
9 Notable Biotechs Presenting At This Year's ASH Meeting
Yahoo
ASH
Bluebird Bio
LentiGlobin
Ziopharm Oncology
Bellicum
BPX-501
Spark Therapeutics
SPK-8011
Biomarin
BMN 270
Juno Therapeutics
CAR-T
Novartis
Geron
imetelstat
Immunogen
IMGN632
IMGN779
Flag link:
Agios spotlights promising data for IDH1 drug, putting it on the path to FDA submission
Agios spotlights promising data for IDH1 drug, putting it on the path to FDA submission
Endpoints
Agios Pharmaceuticals
ASH
FDA
IDH1
ivosidenib
Flag link:
#ASH17: The big loser in CAR-T, Juno is making a bid to seize the fast lane to frontrunner status
#ASH17: The big loser in CAR-T, Juno is making a bid to seize the fast lane to frontrunner status
Endpoints
ASH
CAR-T
Juno Therapeutics
JCAR017
Flag link:
bluebird bio Pauses During 2017 Data Blitz
bluebird bio Pauses During 2017 Data Blitz
Motley Fool
Bluebird Bio
gene therapy
earnings
ASH
Flag link:
Novartis' Big News at ASH? It's Still in the CAR-T Race
Novartis' Big News at ASH? It's Still in the CAR-T Race
Motley Fool
Novartis
ASH
CAR-T
CTL-019
Flag link:
As Humira readies for biosimilar rivals, AbbVie looks to ASH to build oncology momentum
As Humira readies for biosimilar rivals, AbbVie looks to ASH to build oncology momentum
Fierce Pharma
Humira
AbbVie
biosimilars
ASH
Flag link:
2 Pharmas That Should Move After 55th ASH Meeting
2 Pharmas That Should Move After 55th ASH Meeting
Seeking Alpha
ASH
Iclusig
Ariad Pharmaceuticals
SL-401
CML
Stemline
Flag link:
The Winner of ASH 2010: Seattle Genetics
The Winner of ASH 2010: Seattle Genetics
Seeking Alpha
ASH
Seattle Genetics
Celgene
GSK
Immunogen
Micromet
Novartis
Pfizer
YM BioSciences
Sanofi
Flag link:
Celgene in ASH Abstract Spotlight
Celgene in ASH Abstract Spotlight
TheStreet.com
Celgene
ASH
Revlimid
Flag link: